However, recent PCa screening trials highlighted the limitations of using PSA—namely, that PSA screening does not significantly reduce mortality in PCa patients and is associated with a high risk of overdiagnosis [46,47]. This evidence concerns the gene KLK3 and posterior cortical atrophy.